ClinicalTrials.gg
CompletedNCT01021293Updated Jan 21, 2020Results posted

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

A Phase 3 interventional study of Poliorix™ and Oral Poliovirus vaccine in Poliomyelitis and Poliomyelitis Vaccines, sponsored by GlaxoSmithKline. Completed at 1 site in China. Open to participants aged 60 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,101
Allocation
Randomized
Ages
60 Days to 90 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis — 3 open to participants now, 3 under way, none of them phase 3. Poliovirus Vaccine, Inactivated · Poliomyelitis.

Enrollment
5th of 18
1,101 · median 672
Started
2009
with 1 other
Phase 3
4 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
2 of 18
GlaxoSmithKline

Among the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, this one is the 5th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 2nd registered.

Poliomyelitis

275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.

Browse Poliomyelitis studies →

Open to participants now

3 of the 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Poliovirus Vaccine, Inactivated

Poliovirus Vaccine, Inactivated: first FDA approval 2002 (Pediarix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 60 Days to 90 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing Poliovirus Vaccine, Inactivated in Poliomyelitis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.

03

Conditions studied

  • Poliomyelitis
  • Poliomyelitis Vaccines

Browse trials for

Keywords

  • Poliorix
  • IPV
04

Who can participate

Ages eligible
60 Days to 90 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female infant between, and including, 60 and 90 days of age at the time of the first vaccination.
  • Born after a gestation period of 36 to 42 weeks inclusive.
  • Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative (LAR) (s) can and will comply with the requirements of the protocol.
  • Written obtained from the parent(s)/LAR(s) of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs since birth.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with exception of DTP, Hib and/or vaccine(s).
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Evidence of previous or intercurrent poliomyelitis disease or vaccination.
  • History of seizures or progressive neurological disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of any reaction or likely to be exacerbated by any component of the vaccine(s).
  • Major congenital defects or serious chronic illness.
  • Child in care.

The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved and if no other exclusion criteria are met:

  • Current febrile illness or axillary temperature > 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,101 participants (actual)

Study arms

  • Experimental
    Poliorix Group

    Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.

    Biological: Poliorix™

  • Active comparator
    Control Group

    Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.

    Biological: Oral Poliovirus vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3

    A seroprotected subject was defined as a vaccinated subject with anti-polio types 1, 2 and 3 titers greater than or equal to (≥) 8 effective dose 50 (ED50).

    Time frame: At Month 3, one month after the third vaccine dose

Secondary outcomes

  1. Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3

    A seroprotected subject was defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 titers ≥ 8 ED50.

    Time frame: At Day 0, prior to the first vaccine dose

  2. Anti-poliovirus Types 1, 2 and 3 Antibody Titers

    Antibody titers were presented as geometric mean titers (GMTs).

    Time frame: Prior to the first vaccine dose (Day 0) and one month after the third vaccine dose (Month 3)

  3. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure concerns subjects from the Poliorix Group only.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following each vaccine dose and across doses

  4. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were drowsiness, gastrointestinal symptoms, irritability/fussiness, loss of appetite and fever \[defined as axillary temperature higher than (\>) 37.0°C degrees Celsius\]. Gastrointestinal symptoms included nausea, vomiting, diarrhoea and/or abdominal pain. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 gastrointestinal symptoms = gastrointestinal symptoms that prevented normal activity. Grade 3 fever= temperature \> 39°C. Related = symptom assessed by the investigator as causally related to the vaccination.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following each vaccine dose and across doses

  5. Number of Subjects With Any Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

    Time frame: Within the 31-day (Days 0-30) post-vaccination period

  6. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity.

    Time frame: During the entire study period (from Day 0 to Month 3)

07

Results

Posted Apr 25, 2017

Participant flow

Of the 1101 enrolled subjects, one subject was not randomised and administered any vaccine as the parents of the subject refused to vaccinate their child after blood collection at Visit 1 and withdrew their consent.

Participant flow — Overall Study
MilestonePoliorix GroupControl Group
Started550550
Completed538526
Not completed1224
Withdrew: Serious adverse event21
Withdrew: Adverse event21
Withdrew: Withdrawal by subject13
Withdrew: Migrated/moved from study area618
Withdrew: Lost to follow-up11

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3

A seroprotected subject was defined as a vaccinated subject with anti-polio types 1, 2 and 3 titers greater than or equal to (≥) 8 effective dose 50 (ED50).

Time frame:
At Month 3, one month after the third vaccine dose
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3
ParticipantsPoliorix GroupControl Group
Anti-poliovirus 1306296
Anti-poliovirus 2306296
Anti-poliovirus 3306291
Statistical analysis
  • Poliorix Group vs Control Group · Difference in seroprotection rate: 0 · 95% CI -1.28 to 1.24
  • Poliorix Group vs Control Group · Difference in seroprotection rate: 0 · 95% CI -1.28 to 1.24
  • Poliorix Group vs Control Group · Difference in seroprotection rate: -1.69 · 95% CI -3.9 to -0.44
SecondaryNumber of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3

A seroprotected subject was defined as a vaccinated subject with anti-poliovirus types 1, 2 and 3 titers ≥ 8 ED50.

Time frame:
At Day 0, prior to the first vaccine dose
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Poliovirus Types 1, 2 and 3
ParticipantsPoliorix GroupControl Group
Anti-poliovirus 1131113
Anti-poliovirus 29399
Anti-poliovirus 34852
SecondaryAnti-poliovirus Types 1, 2 and 3 Antibody Titers

Antibody titers were presented as geometric mean titers (GMTs).

Time frame:
Prior to the first vaccine dose (Day 0) and one month after the third vaccine dose (Month 3)
Reported as:
Geometric mean · Titers
Anti-poliovirus Types 1, 2 and 3 Antibody Titers
TitersPoliorix GroupControl Group
Anti-poliovirus 1, D08.7 (7.6 to 9.8)7.8 (6.9 to 8.9)
Anti-poliovirus 1, M3485.1 (436.7 to 538.9)2817 (2479.5 to 3200.4)
Anti-poliovirus 2, D06.5 (5.9 to 7.1)7.2 (6.5 to 8.1)
Anti-poliovirus 2, M3234.3 (209 to 262.6)468.5 (416.6 to 526.9)
Anti-poliovirus 3, D05.2 (4.8 to 5.7)5.2 (4.8 to 5.7)
Anti-poliovirus 3, M3824.3 (725.3 to 936.9)423.4 (363.3 to 493.3)
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any local symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure concerns subjects from the Poliorix Group only.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following each vaccine dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsPoliorix Group
Any Pain, Dose 180
Grade 3 Pain, Dose 11
Any Redness, Dose 120
Grade 3 Redness, Dose 10
Any Swelling, Dose 19
Grade 3 Swelling, Dose 10
Any Pain, Dose 258
Grade 3 Pain, Dose 22
Any Redness, Dose 223
Grade 3 Redness, Dose 21
Any Swelling, Dose 28
Grade 3 Swelling, Dose 21
Any Pain, Dose 341
Grade 3 Pain, Dose 30
Any Redness, Dose 315
Grade 3 Redness, Dose 30
Any Swelling, Dose 36
Grade 3 Swelling, Dose 30
Any Pain, Across doses113
Grade 3 Pain, Across doses3
Any Redness, Across doses46
Grade 3 Redness, Across doses1
Any Swelling, Across doses18
Grade 3 Swelling, Across doses1
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were drowsiness, gastrointestinal symptoms, irritability/fussiness, loss of appetite and fever \[defined as axillary temperature higher than (\>) 37.0°C degrees Celsius\]. Gastrointestinal symptoms included nausea, vomiting, diarrhoea and/or abdominal pain. Any = occurrence of any general symptom regardless of intensity grade or relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 gastrointestinal symptoms = gastrointestinal symptoms that prevented normal activity. Grade 3 fever= temperature \> 39°C. Related = symptom assessed by the investigator as causally related to the vaccination.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following each vaccine dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsPoliorix GroupControl Group
Any Drowsiness, Dose 19975
Grade 3 Drowsiness, Dose 101
Related Drowsiness, Dose 17151
Any Gastrointestinal Symptoms, Dose 110289
Grade 3 Gastrointestinal, Dose 102
Related Gastrointestinal, Dose 14443
Any Irritability/Fussiness, Dose 1160151
Grade 3 Irritability/Fussiness, Dose 115
Related Irritability/Fussiness, Dose 1130105
Any Loss of appetite, Dose 18283
Grade 3 Loss of appetite, Dose 101
Related Loss of appetite, Dose 15447
Any temperature, Dose 13920
Grade 3 temperature, Dose 100
Related temperature, Dose 12810
Any Drowsiness, Dose 26850
Grade 3 Drowsiness, Dose 220
Related Drowsiness, Dose 25125
Any Gastrointestinal, Dose 26667
Grade 3 Gastrointestinal, Dose 221
Related Gastrointestinal, Dose 23235
Any Irritability/Fussiness, Dose 212186
Grade 3 Irritability/Fussiness, Dose 272
Related Irritability/Fussiness, Dose 210550
Any Loss of appetite, Dose 27078
Grade 3 Loss of appetite, Dose 230
Related Loss of appetite, Dose 24847
Any temperature, Dose 23926
Grade 3 temperature, Dose 221
Related temperature, Dose 22911
Any Drowsiness, Dose 34745
Grade 3 Drowsiness, Dose 321
Related Drowsiness, Dose 33625
Any Gastrointestinal, Dose 34667
Grade 3 Gastrointestinal, Dose 330
Related Gastrointestinal, Dose 31625
Any Irritability/Fussiness, Dose 38772
Grade 3 Irritability/Fussiness, Dose 322
Related Irritability/Fussiness, Dose 37744
Any Loss of appetite, Dose 35264
Grade 3 Loss of appetite, Dose 300
Related Loss of appetite, Dose 33436
Any temperature, Dose 33332
Grade 3 temperature, Dose 302
Related temperature, Dose 31817
Any Drowsiness, Across doses140125
Grade 3 Drowsiness, Across doses42
Related Drowsiness, Across doses11580
Any Gastrointestinal, Across doses154156
Grade 3 Gastrointestinal, Across doses53
Related Gastrointestinal, Across doses7687
Any Irritability, Across doses244216
Grade 3 Irritability, Across doses109
Related Irritability, Across doses214159
Any Loss of appetite, Across doses147168
Grade 3 Loss of appetite, Across doses31
Related Loss of appetite, Across doses109109
Any Fever, Across doses9971
Grade 3 Fever, Across doses23
Related Fever, Across doses6836
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Time frame:
Within the 31-day (Days 0-30) post-vaccination period
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs)
ParticipantsPoliorix GroupControl Group
Number of Subjects With Any Unsolicited Adverse Events (AEs)155162
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity.

Time frame:
During the entire study period (from Day 0 to Month 3)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsPoliorix GroupControl Group
Number of Subjects With Serious Adverse Events (SAEs)36

Adverse events

Collected over Solicited local and general symptoms: during the 4-day (Days 0-3) post-vaccination period. Unsolicited AEs: within the 31-day (Days 0-30) post-vaccination period. SAEs: during the entire study period (from Day 0 up to Month 3).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Poliorix Group0/550 (0%)3/550 (0.5%)391/550 (71.1%)
Control Group0/550 (0%)6/550 (1.1%)366/550 (66.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPoliorix GroupControl Group
BronchopneumoniaInfections and infestations0/5502/550
Cardiac failureCardiac disorders0/5501/550
Respiratory failureRespiratory, thoracic and mediastinal disorders0/5501/550
EpilepsyNervous system disorders0/5501/550
HydrocephalusNervous system disorders1/5500/550
Abdominal distensionGastrointestinal disorders0/5501/550
DiarrhoeaGastrointestinal disorders1/5500/550
EnteritisGastrointestinal disorders0/5501/550
BronchitisInfections and infestations0/5501/550
Herpes zosterInfections and infestations1/5500/550
Most frequent other events
Most frequent other events
EventPoliorix GroupControl Group
Irritability/FussinessGeneral disorders244/550216/550
Loss of appetiteGeneral disorders147/550168/550
Gastrointestinal symptomsGeneral disorders154/550156/550
DrowsinessGeneral disorders140/550125/550
PainGeneral disorders113/5500/550
Upper respiratory tract infectionInfections and infestations99/55097/550
Fever (Axillary)General disorders99/55071/550
RednessGeneral disorders46/5500/550
NasopharyngitisInfections and infestations32/55038/550

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)Poliorix GroupControl GroupTotal
Mean10 ± 1.1610.1 ± 1.1810.05 ± 1.17
Sex: Female, Male
Sex: Female, Male(Participants)Poliorix GroupControl GroupTotal
Female268259527
Male282291573
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Poliorix GroupControl GroupTotal
Asian-Chinese heritage5505501100
08

Study locations

1 site
  • GSK Investigational Site
    Wuzhou, Guangxi, China
09

References and documents

Publications

  • Li R et al. Immunogenicity and safety of an inactivated poliovirus vaccine in Chinese infants. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). The Melbourne, The Australia, 16-19 November 2011.
  • Li R, Li CG, Li Y, Liu Y, Zhao H, Chen X, Kuriyakose S, Van Der Meeren O, Hardt K, Hezareh M, Roy-Ghanta S. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 2016 Mar 14;34(12):1436-43. doi: 10.1016/j.vaccine.2016.02.010. Epub 2016 Feb 9. PubMed 26873055 ↗

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2009 to primary completion in Jul 2010, 7 months.

Results were first posted in Apr 2017, 6 years 9 months after primary completion. A results delay was requested in Dec 2010.

Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 7 months is below that.

Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2009
First posted
Nov 26, 2009
StartActual
Nov 28, 2009
Primary completionActual
Jul 5, 2010
CompletionActual
Jul 5, 2010
Results delay requested
Dec 24, 2010
Results first posted
Apr 25, 2017
Last update
Jan 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01021293
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 26, 2009
Start date
Nov 28, 2009
Primary completion
Jul 5, 2010
Completion
Jul 5, 2010
Results posted
Apr 25, 2017
Last update
Jan 21, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poliovirus Vaccine, Inactivated

Start the discussion